Tetrabenazine

PUNE, India, June 9, 2025 /PRNewswire/ -- According to the latest research by Credence Research, the global Nontuberculous Mycobacterial (NTM) Diagnostic Market was valued at USD 1,814.8 million in 2023 and is projected to reach USD 3,261.1 million by 2032, growing at a compound annual growth rate (CAGR) of 6.64% during the forecast period. The rising incidence of NTM infections, especially among immunocompromised patients and individuals with chronic pulmonary conditions, is a primary factor driving market demand. Technological advancements in molecular diagnostics and imaging techniques are significantly enhancing detection accuracy and speed, leading to faster diagnosis and improved clinical outcomes. Healthcare providers are increasingly adopting advanced diagnostic platforms to address the complexities of identifying NTM species, which often mimic other pulmonary disorders. This shift is further supported by growing awareness of NTM-related diseases and stronger clinical guidelines for early screening and diagnosis. Expanding healthcare infrastructure across emerging markets, coupled with increased investments in R&D by diagnostics companies, is expected to accelerate market expansion over the coming years. Browse the report and understand how it can benefit your business strategy- Key Growth Determinants: Nontuberculous Mycobacterial (NTM) Diagnostic Market The growth of the NTM Diagnostic Market is primarily driven by the rising global prevalence of NTM infections, particularly among the aging population and individuals with underlying lung conditions such as COPD, bronchiectasis, and cystic fibrosis. As awareness of these infections increases among healthcare professionals, the demand for timely and accurate diagnostic solutions is expanding. This trend is supported by an uptick in hospital admissions and outpatient consultations related to unexplained pulmonary symptoms, where NTM is an emerging differential diagnosis. Another key growth determinant is the rapid advancement in diagnostic technologies. Innovations in molecular diagnostics, PCR-based assays, and next-generation sequencing (NGS) are enabling faster, more precise identification of various NTM species, overcoming the limitations of traditional culture methods. Furthermore, increased funding for infectious disease research and growing collaborations between public health organizations and diagnostic manufacturers are creating favorable conditions for product development and market penetration. The rising implementation of clinical guidelines recommending early testing for at-risk populations is also bolstering the adoption of advanced NTM diagnostics globally. Key Growth Barriers: Nontuberculous Mycobacterial (NTM) Diagnostic Market Limited Awareness and Misdiagnosis Many clinicians and patients remain unaware of NTM infections, which often mimic tuberculosis or other chronic pulmonary conditions. This lack of awareness leads to frequent misdiagnosis or delayed testing, particularly in settings with limited diagnostic infrastructure. Diagnostic Complexity and Inaccessibility Accurate identification of NTM species is essential for effective treatment, but traditional culture methods are time-consuming and may lack sensitivity. Advanced molecular diagnostic tools, though more effective, are not widely accessible in many regions, especially in developing markets. Resource Constraints in Healthcare Facilities Comprehensive NTM diagnostics require specialized laboratory equipment, trained personnel, and standardized testing protocols. Many healthcare systems, especially in low- and middle-income countries, face limitations in implementing such advanced diagnostics. Regulatory and Reimbursement Challenges Navigating regulatory approval for new diagnostic tools can be time-consuming and costly. In addition, limited reimbursement policies for advanced NTM diagnostic tests discourage healthcare providers from adopting innovative solutions. Segmentation Based on Diagnostic Method: Nucleic Acid Amplification Tests (NAAT) Microscopy Culture-based Methods Biochemical Tests Immunological Tests PCR Others Based on Infection Type: Pulmonary Cutaneous Disseminated Gastrointestinal Others Based on End-User: Hospitals & Clinics Diagnostic Laboratories Others Based on region North America The U.S. Canada Mexico Europe Germany France UK. Italy Spain Rest of Europe Asia Pacific China Japan India South Korea South-east Asia Rest of Asia Pacific Latin America Brazil Argentina Rest of Latin America Middle East & Africa GCC Countries South Africa The Rest of the Middle East and Africa Preview the report with a detailed sample and understand how it can benefit your business strategy. Request a free sample today - Regional Analysis: Nontuberculous Mycobacterial (NTM) Diagnostic Market North America holds the largest share of the global NTM Diagnostic Market, accounting for approximately 39% of total revenue in 2023. This dominance is driven by advanced healthcare infrastructure, widespread use of molecular diagnostic technologies, and high awareness of NTM-related diseases. The presence of major diagnostic companies and strong R&D funding further support market growth in the United States and Canada. Europe follows with around 27% of the market share. Countries like Germany, the UK, and France are key contributors, supported by growing recognition of NTM infections, aging populations, and well-established public health systems. Increased focus on early diagnosis and the adoption of advanced testing tools continue to fuel regional demand. Asia-Pacific accounts for roughly 23% of the global market. Rapid improvements in healthcare infrastructure, growing patient awareness, and increased investments in diagnostic technologies are propelling growth in China, Japan, South Korea, and India. Partnerships between international diagnostic firms and regional players are expanding access to accurate NTM testing. Latin America represents about 6% of the market, led by Brazil, Mexico, and Argentina. Market growth is supported by public health campaigns and improved diagnostic capabilities, though infrastructure disparities in remote areas remain a challenge. Middle East & Africa comprise the smallest share, approximately 5% in 2023. While diagnostic capacity remains limited in many parts of the region, targeted investments in laboratory services and healthcare modernization—especially in the GCC and South Africa—are gradually improving market potential. Credence Research's Competitive Landscape Analysis Credence Research's Competitive Landscape Analysis presents a clear and focused view of key industry players in the NTM diagnostic segment with a spotlight on strategic strengths and market positioning: Credence Research identifies a handful of dominant multinational diagnostics firms— Thermo Fisher Scientific Inc., F. Hoffmann‑La Roche Ltd, Becton, Dickinson & Company (BD), and bioMérieux SA—as frontrunners in the global NTM diagnostic market. These companies differentiate themselves via wide-ranging product portfolios that encompass both molecular and immunological diagnostic tools. They cater to centralized laboratory settings and decentralized testing environments, ensuring flexibility across different healthcare infrastructures. Their strong investment in R&D, global distribution networks, and robust service support contribute to their sustained competitive edge and rapid product adoption. Through its analysis, Credence Research highlights how these industry leaders are not only maintaining market dominance but also expanding access to advanced NTM diagnostic solutions via collaborations, innovative product development, and targeted regional strategies—positioning themselves to capitalise on the projected market growth. Tailor the report to align with your specific business needs and gain targeted insights. Request Full Report Here- Key Player Analysis Thermo Fisher Scientific Inc Hoffmann-La Roche Ltd Becton, Dickinson and Company (BD) bioMérieux SA Bruker Corporation SD Biosensor Bioneer Seegene Inc. Recent Industry Developments June 2025 – Thermo Fisher Scientific introduced two advanced mass spectrometry instruments—the Orbitrap Astral Zoom and Orbitrap Excedion Pro—during the ASMS conference. Designed primarily for proteomics and biopharma applications, these systems deliver enhanced speed and sensitivity, significantly advancing the analysis of complex biological samples. Their improved resolution and throughput have potential applications in infectious disease diagnostics, including NTM-related testing. December 2024 – Shanghai MicuRx Pharmaceutical (688373.SH) announced that the U.S. FDA granted Orphan Drug Designation (ODD) to its investigational anti-infective drug MRX-5 for the treatment of NTM infections, representing a significant step in developing targeted therapies for this condition. September 2023 – QIAGEN entered a strategic partnership with a major South Asian healthcare provider to integrate its proprietary diagnostics into regional laboratories, enhancing capabilities for detecting and managing NTM infections. August 2023 – bioMérieux expanded its infectious disease portfolio through the acquisition of a biotech company specializing in NTM diagnostics. July 2023 – Hologic, Inc. secured regulatory approval for a new diagnostic test specifically developed to identify NTM infections, reinforcing its commitment to infectious disease diagnostics. January 2022 – Gaelan Medical Trade LLC partnered with RedHill Biopharma Ltd. to distribute Talicia (omeprazole magnesium, amoxicillin, and rifabutin) in the United Arab Emirates. Though primarily approved for H. pylori, its components hold relevance in mycobacterial infection strategies. February 2021 – Koninklijke Philips N.V. completed the acquisition of BioTelemetry, Inc., a leader in remote monitoring and diagnostics, potentially expanding future integration of infectious disease tracking technologies. Reasons to Purchase this Report: Gain a comprehensive understanding of the market through qualitative and quantitative analyses, considering both economic and non-economic factors, with segmentation and sub-segmentation details provided in terms of market value (USD Billion). Identify regions and segments expected to experience the fastest growth or dominate the market, with a detailed analysis of geographic consumption patterns and the factors driving or hindering market performance in each region. Stay informed about the competitive environment, with rankings of major players, recent product and service launches, partnerships, business expansions, and acquisitions from the past five years. Access detailed profiles of major market players, including company overviews, insights, product benchmarking, and SWOT analysis, to understand competitive advantages and market positioning. Explore the present and forecasted market landscape, with insights into growth opportunities, market drivers, challenges, and constraints for both developed and emerging regions. Benefit from Porter's Five Forces analysis and Value Chain insights to evaluate various market perspectives and competitive dynamics. Understand the evolving market scenario, including potential growth opportunities and trends expected in the coming years. Browse the report and understand how it can benefit your business strategy - Discover additional reports tailored to your industry needs Ocular Drug Delivery System Market - Pharma Grade Synthetic Camphor Market - Topical Drug Delivery Market - Lidocaine Market - Dermatology and Eye Care Services Market - Metabolism Assays Market - Dental Implantology Drill Bit Market - Dental Implantology Drill Bit Market - Tetrabenazine Market - Follow Us: About Us: Credence Research is a viable intelligence and market research platform that provides quantitative B2B research to more than 2000 clients worldwide and is built on the Give principle. The company is a market research and consulting firm serving governments, non-legislative associations, non-profit organizations, and various organizations worldwide. We help our clients improve their execution in a lasting way and understand their most imperative objectives. Contact Us Mitul Dean Tower C-1105 , S 25, Akash Tower, Vishal Nahar, Pimple Nilakh, Haveli, Pune – 411027, India [email protected] Logo - SOURCE Credence Research Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

同写意年度巨献！！7月25-26日，邀您相聚金鸡湖畔，与5000人一起为中国医药创新“同写意”！2025年5月29日，海创药业的氘恩扎鲁胺（商品名：海纳安）获批上市，成为全球第四款氘代药物。这一事件不仅标志着中国在改良型创新药领域的突破，更揭示了氘代技术从边缘探索走向主流赛道的产业逻辑。但比单一药物更值得关注的是，全球氘代药物市场正以年复合增长率超15%的态势扩张——从梯瓦制药的安泰坦®开创先河，到泽璟制药的多纳非尼实现肝癌治疗突破，再到Concert公司15条临床管线同步推进，这场“氢换氘”的分子魔术已重塑治疗边界。TONACEA01价值重构氘，这个看似神秘的氢同位素，正悄然改变全球药物研发的竞争格局。当氢原子（H）被替换为含有一个中子的氘原子（D），药物分子的命运也随之改变。这种被称为“氘代”的技术创新，成为制药界近年来最受关注的突破方向之一。氘代药物的核心在于动力学同位素效应（DKIE）。碳-氘键的裂解能比碳-氢键高5-10倍，这一特性直接作用于药物代谢路径：通过减缓肝药酶（如CYP450）对活性分子的氧化代谢，延长半衰期并减少毒性代谢产物生成。以氘恩扎鲁胺为例，其半衰期从原研药的4.5天延长至7.8天，CYP2C8代谢率降低62%，这使得患者给药频率从每日两次减少至每日一次，且肝脏毒性显著下降。全球首个氘代药物安泰坦®（氘丁苯那嗪片）的上市，验证了这条技术路径的可行性。2020年，梯瓦公司的这款新药在中国获批，用于治疗亨廷顿病相关的舞蹈病及迟发性运动障碍，成为首个进入中国医保的氘代药物。总体来说，氘代药物的奥妙在于分子键能的微妙变化，碳-氘键比碳-氢键更强，断裂需要更高能量；药物代谢速率显著减缓，活性成分暴露时间延长；毒副产物生成减少，用药安全性提升。这种“代谢调控”的价值在肿瘤治疗中尤为突出。例如，泽璟制药的多纳非尼（氘代索拉非尼）通过选择性氘代，将索拉非尼的VEGFR抑制活性提升3倍，同时将皮肤毒性发生率从原研药的47%降至29%。这种“增效减毒”的特性，使其在肝癌一线治疗中实现ORR（客观缓解率）对比原研药的提升（12.1% vs 7.3%）。表：全球主要氘代药物研发进展TONACEA02本土竞速当国际制药巨头还在观望氘代技术的商业前景时，中国创新药企已在这条赛道上加速超车。从泽璟制药的多纳非尼，到海创药业的氘恩扎鲁胺，再到同源康医药的TY-9591，本土药企正构筑起一条覆盖肿瘤、代谢疾病、自身免疫性疾病的氘代药物管线。以海创药业的成长轨迹为例，可以勾勒出中国氘代药物开发的特征路径。2013-2018年，海创药业完成“氘代药物研发平台”布局，同步启动PROTAC技术研究，而在2018-2021年间，其在研管线拓展至10个项目，4项进入临床阶段。2022年，公司成功在科创板上市，采用第五套上市标准，成为未盈利生物科技公司上市的一员，2023年11月，氘恩扎鲁胺软胶囊新药上市申请获NMPA受理，到了今天正式上市。而泽璟制药的氘代药物多纳非尼已证明本土创新的临床价值。这款索拉非尼的氘代药物在头对头试验中击败原研药，成为首个在疗效上超越进口原研的国产氘代药。而正大天晴的TQA-3326（氘代达卡他韦）则瞄准丙肝治疗市场，2018年已进入I期临床试验。“氘代药物研发赛道已显拥挤”，曾有文章在2019年发出预警。随着入局者增多，专利风险也水涨船高。表：中国主要氘代药物研发企业及管线氘代药物的兴起引发业界对创新程度的争议。批评者认为氘代仅是分子修饰策略，而非真正原始创新。支持者则指出，成功的氘代药物需克服代谢途径优化、晶型研究、剂型设计等系统性挑战，其科技含量不亚于全新药物开发。专利风险是悬在氘代药物头上的达摩克利斯之剑。行业人士警示：“氘代药物可能面临原研商的诉讼，进入这个区域冒险的，未来要么赔要么赚”，对此，也有公司提出解决方案，海创药业通过全球专利布局化解这一风险——公司拥有氘恩扎鲁胺的化合物专利，保护期至2032年，比原研药专利更长。氘代药物的崛起揭示了一个产业真理：在药物研发的“渐进式创新”与“颠覆式创新”之间，存在广阔的中间地带。当海创药业用氘代技术突破前列腺癌治疗瓶颈，当泽璟制药在肝癌红海中开辟新路径，中国药企正在证明——即便是分子层面的微调，只要精准切入临床痛点，同样能创造价值。然而，技术的“捷径”属性不应成为创新惰性的借口。在氘代技术的光环下，中国创新药更需要底层靶点发现能力与临床开发策略的双重进化。参考资料：https://www.cphi.cn/news/show-173671.htmlhttps://caifuhao.eastmoney.com/news/20250317115206025640780http://m.001ce.com/zixun/licai/2022/0414/100051911.htmlhttps://cs.com.cn/ssgs/gsxw/202404/t20240415_6401924.html